12:00 AM
 | 
Nov 23, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lomitapide: Additional Phase III data

Additional data from an ongoing, open-label Phase III trial in 14 evaluable patients treated for at least 26 weeks showed that lomitapide titrated up to 60 mg/day reduced mean LDL-C by 49%. Average baseline LDL-C levels were...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >